Acute nephrotoxicity of tacrolimus and sirolimus in renal isografts: Differential intragraft expression of transforming growth factor-β1 and α-smooth muscle actin

Transplantation

Volumn 78, Issue 3, 2004, Pages 338-344

  Ninova, Dora ^a   Covarrubias, Marco ^a   Rea, David J ^a   Park, Walter D ^a   Grande, Joseph P ^a   Stegall, Mark D ^a  

^a Mayo Clinic   (United States)

Author keywords

smooth muscle actin; Nephrotoxicity; Sirolimus; Tacrolimus; TGF 1

Indexed keywords

ALPHA ACTIN; CREATININE; RAPAMYCIN; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VACUOLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG MEGADOSE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTERSTITIAL NEPHRITIS; KIDNEY FIBROSIS; KIDNEY ISCHEMIA; KIDNEY TRANSPLANTATION; MALE; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY; UNINEPHRECTOMY;

ACTINS; ANIMALS; CREATININE; GENE EXPRESSION REGULATION; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATION; KIDNEY; KIDNEY TRANSPLANTATION; KIDNEY TUBULES; MALE; RATS; RATS, INBRED LEW; SIROLIMUS; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; TRANSPLANTATION, ISOGENEIC;

EID: 4143078169     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000128837.07640.AE     Document Type: Article

References (35)

1. Olyaei AJ, de Mattos AM, Bennett WM. Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care 2001; 7: 384.
2. Muller T, Ruffingshofer D, Bidmon B, et al. Reduction of delayed renal allograft function using sequential immunosuppression. Pediatr Nephrol 2001; 16: 613.
3. Gonwa TA, Mai ML, Smith LB, et al. Immunosuppression for delayed or slow graft function in primary cadaveric renal transplantation: use of low dose tacrolimus therapy with post-operative administration of anti-CD25 monoclonal antibody. Clin Transplant 2002; 16: 144.
4. Sehgal SN. Rapamune (sirolimus, rapamycin): an overview and mechanism of action. Ther Drug Monit 1995; 17: 660.
5. Andoh TF, Choi S-O, Wakba IM, et al. Beneficial effect of mycophenolate mofetil in sirolimus induced delayed renal function in post-ischemic rat kidney. Am J Transplant 2002; 3: 161 (Abstract).
6. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416.
7. Davis C. Sirolimus delays renal allograft recovery. Am J Transplant 2003; 3: 363.
8. Shihab FS, Bennett WM, Tanner AM, et al. Mechanism of fibrosis in experimental tacrolimus nephrotoxicity. Transplantation 1997; 64: 1829.
9. McCartney-Francis NL, Frazier-Jessen M, Wahl SM. TGF-beta: A balancing act. Int Rev Immunol 1998; 16: 553.
10. Mozes MM, Bottinger EP, Jacot TA, et al. Renal expression of fibrotic matrix proteins and of transforming growth factor-beta (TGF-beta) isoforms in TGF-beta transgenic mice. J Am Soc Nephrol 1999; 10: 271.
11. Kagami S, Border WA, Ruoslahti E, et al. Coordinated expression of beta 1 integrins and transforming growth factor-beta-induced matrix proteins in glomerulonephritis. Lab Invest 1993; 69: 68.
12. Nicholson ML, Waller JR, Bicknell GR. Renal transplant fibrosis correlates with intragraft expression of tissue inhibitor of metalloproteinase messenger RNA. Br J Surg 2002; 89: 933.
13. Basile DP, Rovak JM, Martin DR, et al. Increased transforming growth factor-β1 expression in regenerating rat renal tubules following ischemic injury. Am J Physiol 1996; 270(3 Pt 2): F500-509.
14. Lewis MP, Norman JT. Differential response of activated versus non-activated renal fibroblasts to tubular epithelial cells: a model of initiation and progression of fibrosis? Exp Nephrol 1998; 6: 132.
15. Powell DW, Mifflin R, Valentich J, et al. Myofibroblasts. I: paracrine cells important in health and disease. Am J Physiol 1999; 277: C1.
16. Stahl PJ, Felsen D. Transforming growth factor-β, basement membrane, and epithelial-mesenchymal transdifferentiation. Implications for fibrosis in kidney disease. Am J Pathol 2001; 159: 1187.
17. Zeisberg M, Bonner G, Maeshima Y, et al. Renal fibrosis. Collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001; 159: 1313.
18. Pankewycz OG, Miao L, Isaacs R, et al. Increased renal tubular expression of transforming growth factor beta in human allografts correlates with cyclosporine toxicity. Kidney Int 1996; 50: 1634.
19. Langham RG, Egan MK, Dowling JP, et al. Transforming growth factor-beta 1 and tumor growth factor-beta-inducible gene-H3 in nonrenal transplant cyclosporine nephropathy. Transplantation 2001; 72: 1826.
20. Lee S. An improved technique of renal transplantation in the rat. Surgery 1967; 61: 771.
21. Taylor PJ, Salm P, Lynch SV, et al. Simultaneous quantification of tacrolimus and sirolimus, in human blood, by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2000; 22: 608.
22. Racusen LC, Solez K, Colvin RB, et al. The Banff 97 working classification for renal allograft pathology. Kidney Int 1999; 55: 713.
23. Choi ME, Liu A, Ballermann BJ. Differential expression of transforming growth factor-beta receptors in rat kidney development. Am J Physiol 1997; 273: F386.
24. Sutaria PM, Ohebshalom M, McCaffrey TA, et al. Transforming growth factor-β receptor type I and II are expressed in renal tubules and are increased after chronic unilateral ureteral obstruction. Life Sci 1998; 62: 1965.
25. 1 reduces megalin- and cubilin-mediated endocytosis of albumin in proximal-tubule-derived opossum kidney cells. J Physiol 2003; 552.2: 471.
26. Stegall MD, Park WD, Kim DY, et al. Changes in intragraft gene expression secondary to ischemia reperfusion after cardiac transplantation. Transplantation 2002; 74: 924.
27. Yamamoto T, Noble NA, Miller DE, et al. Sustained expression of TGF-beta 1 underlies development of progressive kidney fibrosis. Kidney Int 1994; 45: 916.
28. Yang J, Liu Y. Dissection of key events in tubular epithelial to myofibroblast transition and its implications in renal interstitial fibrosis. Am J Pathol 2001; 159: 1465.
29. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis 1992; 20: 1.
30. Bai S, Brunner LJ, Stepkowski SM, et al. Effect of low dose cyclosporine and sirolimus on hepatic drug metabolism in the rat. Transplantation 2001; 71(11): 1585.
31. Takada S, Takahara S, Nishimura K, et al. Effect of hepatocyte growth factor on tacrolimus-induced nephrotoxicity in spontaneously hypertensive rats. Transplant Int 1999; 12(1): 27.
32. Tada H, Nakashima A, Awaya A, et al. Effects of thymic hormone on reactive oxygen species-scavengers and renal function in tacrolimus induced nephrotoxicity. Life Sci 2002; 70(10): 1213.
33. Jain S, Bicknell GR, Nicholson ML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000; 87: 1563.
34. Bagnis C, Deray G, Dubois M, et al. Comparative acute nephrotoxicity of FK-506 and cyclosporin in an isolated in situ autoperfused rat kidney model. Am J Nephrol 1997; 17(1): 17.
35. DiJoseph JF, Mihatsch MJ, Sehgal SN. Influence of rat strain on rapamycin's kidney effects. Transplant Proc 1993; 25(1): 714.